BlackRock Discloses 7.9% Stake in Sellas Life Sciences

Sellas Life Sciences shares closed Tuesday up 7% at $12.17 after BlackRock disclosed a 7.9% stake. Retail investors also circulated forecasts pointing to possible European approval of the company's leukemia immunotherapy in 2027 ahead of Phase 3 results.